GhazawiFM.LeM.LagacéFet al. Incidence, mortality, and spatiotemporal distribution of cutaneous malignant melanoma cases across Canada. J Cutan Med Surg. 2019;23(4):394-412.doi:10.1177/120347541985204831132871
2.
TarhiniA.KudchadkarRR. Predictive and on-treatment monitoring biomarkers in advanced melanoma: moving toward personalized medicine. Cancer Treat Rev. 2018;71:8-18.doi:10.1016/j.ctrv.2018.09.00530273812
3.
ZhouS.SikorskiD.XuHet al. Defining the Criteria for Reflex Testing for BRAF Mutations in Cutaneous Melanoma Patients. Cancers. 2021;13(9):2282.doi:10.3390/cancers1309228234068774
4.
CheemaPK.RaphaelS.El-MaraghiRet al. Rate of EGFR mutation testing for patients with nonsquamous non-small-cell lung cancer with implementation of reflex testing by pathologists. Curr Oncol. 2017;24(1):16-22.doi:10.3747/co.24.326628270720
5.
MillerR.WalkerS.ShuiI.BrandtmüllerA.CadwellK.ScherrerE. Epidemiology and survival outcomes in stages II and III cutaneous melanoma: a systematic review. Melanoma Manag. 2020;7(1):MMT39.doi:10.2217/mmt-2019-002232399177
